5-(Bromomethyl)-3-methylisoxazole
- Catalog NO.：A874239
- CAS No. : 36958-61-9
- Molecular Formula：C5H6BrNO
- Molecular Weight： 176.01
1. Please click the
to confirm the discount and stock quantity.2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
| CAS Number | 36958-61-9 | Appearance | |
| Catalog Number | A874239 | MDL Number | MFCD09879901 |
| Molecular Formula | C5H6BrNO | Molecular Weight | 176.01 |
| Boiling Point | 225.6℃ at 760 mmHg | Melting Point | |
| Flash Point | Density | ||
| Synonyms | 5-(Bromomethyl)-3-methylisoxazole | ||
| Storage Condition | Store in a tightly closed container,in a cool and dry place | ||
Safety
| GHS Pictogram |
|
||
| Signal Word | Danger | UN Number | 3265 |
| Hazard Statements | H314-H318 | Class | 8 |
| Precautionary Statements | P280-P305+P351+P338-P310 | Packing Group | Ⅲ |
Description
|
AMD11070, also known as AMD070, X4P-001 and mavorixafor, is an orally bioavailable and potent CXCR4 inhibitor. AMD11070 is an antagonist of SDF-1α ligand binding (IC50 = 12.5 ± 1.3 nM), inhibits SDF-1 mediated calcium flux (IC50 = 9.0 ± 2.0 nM) and SDF-1α mediated activation of the CXCR4 receptor as measured by a Eu-GTP binding assay (IC50 =39.8 ± 2.5 nM) or a [(35)S]-GTPγS binding assay (IC50 =19.0 ± 4.1 nM), and inhibits SDF-1α stimulated chemotaxis (IC50 =19.0 ± 4.0 nM). AMD11070 abrogates melanoma cell migration and is significantly more effective than AMD3100. AMD11070 represents a novel therapeutic strategy for both B-RAF wild-type and mutated melanomas. |
